SB216763

For research use only. Not for use in humans.

目录号：S1075

CAS No. 280744-09-4

SB216763 是一种有效的，选择性GSK-3α抑制剂，IC50为34.3 nM；对GSK-3β具有同样的抑制作用。SB216763 可激活自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1351.27	现货
5mg	RMB 1218.72	现货
10mg	RMB 2208.01	现货
50mg	RMB 7122.58	现货
100mg	RMB 8763.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的SB216763发表文献73篇：

Sci Rep, 2022, 12(1):7

PubMed: 34997030 ( click the link to review the publication )

Biomed Pharmacother, 2022, 145:112432

PubMed: 34798472 ( click the link to review the publication )

J Clin Invest, 2021, 131(6)136098

PubMed: 33720050 ( click the link to review the publication )

Autophagy, 2021, 1-19

PubMed: 34282994 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1205

PubMed: 33801977 ( click the link to review the publication )

Neoplasia, 2021, 23(12):1227-1239

PubMed: 34768109 ( click the link to review the publication )

Neoplasia, 2021, 23(3):304-325

PubMed: 33582407 ( click the link to review the publication )

Transbound Emerg Dis, 2021, 10.1111/tbed.14422

PubMed: 34918880 ( click the link to review the publication )

Mol Med, 2021, 27(1):77

PubMed: 34266379 ( click the link to review the publication )

Biomedicines, 2021, 9(5)579

PubMed: 34065438 ( click the link to review the publication )

JCI Insight, 2021, 6(8)131458

PubMed: 33884962 ( click the link to review the publication )

J Interv Card Electrophysiol, 2021, 10.1007/s10840-021-00963-7

PubMed: 33611692 ( click the link to review the publication )

Int Immunopharmacol, 2021, 94:107428

PubMed: 33581580 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(48):30628-30638

PubMed: 33199625 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

J Neurochem, 2020, 154(4):441-457

PubMed: 31951013 ( click the link to review the publication )

Sci Rep, 2020, 10(1):19723

PubMed: 33184327 ( click the link to review the publication )

Front Microbiol, 2020, 8;11:767

PubMed: 32457708 ( click the link to review the publication )

J Biol Chem, 2020, 295(3):673-689

PubMed: 31780563 ( click the link to review the publication )

RNA, 2020, 13 pii: rna 73528 119

PubMed: 32404348 ( click the link to review the publication )

Front Pharmacol, 2020, 11:812

PubMed: 32595496 ( click the link to review the publication )

Brain Res Bull, 2020, 158:99-107

PubMed: 32070769 ( click the link to review the publication )

J Bioenerg Biomembr, 2020, 52(6):441-451

PubMed: 33196964 ( click the link to review the publication )
Immunopharmacol Immunotoxicol, 2020, 42(1):9-16

PubMed: 31760890 ( click the link to review the publication )

J Invest Surg, 2020, 10.1080/08941939.2019.1705941

PubMed: 32036721 ( click the link to review the publication )

Diabetes Metab Syndr Obes, 2020, 13:3075-3087

PubMed: 32943896 ( click the link to review the publication )

Biosci Rep, 2020, 40(7):BSR20202019

PubMed: 32696949 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4013

PubMed: 31488827 ( click the link to review the publication )

Int J Cancer, 2019, 144(2):389-401

PubMed: 29978469 ( click the link to review the publication )

Redox Biol, 2019, 20:261-274

PubMed: 30384260 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2013594

PubMed: 31641423 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18994-19009

PubMed: 30919976 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Front Physiol, 2019, 10:412

PubMed: 31024348 ( click the link to review the publication )

Int Immunopharmacol, 2019, 74:105717

PubMed: 31254953 ( click the link to review the publication )

Mol Med Rep, 2019, 20(2):1523-1530

PubMed: 31257459 ( click the link to review the publication )

Andrologia, 2019, 51(3):e13200

PubMed: 30467872 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Cancer Res, 2018, 10.1158/0008-5472

PubMed: 29895675 ( click the link to review the publication )

Cell Rep, 2018, 23(6):1665-1677

PubMed: 29742424 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):230

PubMed: 29445085 ( click the link to review the publication )

Aging (Albany NY), 2018, 10(11):3104-3116

PubMed: 30398976 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(6):935-946

PubMed: 29545477 ( click the link to review the publication )

Int J Mol Med, 2018, 42(3):1391-1400

PubMed: 29956736 ( click the link to review the publication )
Neurosci Lett, 2018, 687:207-215

PubMed: 30278248 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 04:18

PubMed: 29872541 ( click the link to review the publication )

Mol Cell, 2017, 68(1):185-197

PubMed: 28943315 ( click the link to review the publication )

Dev Cell, 2017, 41(2):129-142

PubMed: 28441528 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Cell Rep, 2017, 18(13):3167-3177

PubMed: 28355568 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28619760 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 110:101-108

PubMed: 28359686 ( click the link to review the publication )

Hum Cell, 2017, 30(1):11-22

PubMed: 27604750 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(7 Pt A):1579-88

PubMed: 27066979 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Respir Res, 2016, 17:4

PubMed: 26753996 ( click the link to review the publication )

Cell Signal, 2016, 28(12):1826-1832

PubMed: 27566175 ( click the link to review the publication )

Int J Oncol, 2016, 49(5):2163-2172

PubMed: 27599658 ( click the link to review the publication )

Am J Transl Res, 2016, 8(5):1985-97

PubMed: 27347308 ( click the link to review the publication )

Int J Mol Med, 2016, 37(5):1281-9

PubMed: 27035393 ( click the link to review the publication )

Oncotarget, 2016, 7(45):73558-73572

PubMed: 27713153 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):408

PubMed: 25056574 ( click the link to review the publication )

J Immunol, 2014, 192(8):3958-68

PubMed: 24634494 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115854

PubMed: 25541965 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6289-99

PubMed: 25026288 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):454-67

PubMed: 24282277 ( click the link to review the publication )
J Histochem Cytochem, 2013, 61(9):659-70

PubMed: 23761130 ( click the link to review the publication )

产品安全说明书

GSK-3抑制剂选择性比较

生物活性

产品描述

SB216763 是一种有效的，选择性GSK-3α抑制剂，IC50为34.3 nM；对GSK-3β具有同样的抑制作用。SB216763 可激活自噬。

靶点

GSK-3α ^[1] (Cell-free assay)	GSK-3β ^[1] (Cell-free assay)
34.3 nM	~34.3 nM

体外研究

除了抑制GSK-3α,SB 216763也同样有效作用于 GSK-3β，按10 μM 处理，抑制达96%，作用于24 种其他蛋白激酶包括 PKBα 和PDK1时具有最小活性，IC50>10 μM。SB-216763作用于人肝脏细胞，刺激糖原合成，EC50为3.6 μM, 且作用于HEK293 细胞，诱导β-catenin-LEF/TCF相关报告基因的转录，这种作用存在剂量依赖性，按 5 μM处理，诱导达到最大值，增大2.5倍。^[1]与剂量依赖性显著抑制GSK-3 活性一致，SB 216763 保护小脑颗粒神经元免受 LY-294002或钾丧失而诱导的细胞凋亡，这种作用具有浓度依赖性，3 μM 时保护神经达到最高值，与10 mM LiCl作用效果形成对比。3 μM SB 216763完全抑制 LY-294002诱导的鸡背根神经节感觉神经元死亡。5 μM SB 216763 作用于HEK293细胞，显著抑制小脑颗粒神经元中GSK-3依赖的神经元特异性微管相关蛋白的磷酸化，且提高β-catenin细胞质水平，与Wnt调节的 GSK-3抑制效果差不多。^[2] 25-50 μM SB 216763作用于前列腺癌细胞系，包括BXPC-3, MIA-PaCa2, PANC1, ASPC1, 和CFPAC, 降低细胞活力，这种作用存在剂量依赖性，且显著促进凋亡，处理72小时,凋亡达50%,而对HMEC或WI38细胞系没有作用效果。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HEK293	NXT6fGs3TnWwY4Tpc44h[XO\|YYm=			NHjnXXVIdHmlb3flckB{gW62aHHz[UBi[3Srdnn0fUBw\iCKRVuyPVMh[2WubIOsJIlvcGmkaYTpc44hd2ZiR2PLN{1j\XSjLDDFR\|UxRTBwMt88US=>	M2\GfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN\|MyLz5zMkm0NVM{OTxxYU6=
HEK293	MWTGeY5kfGmxbjDhd5NigQ>?			MVTF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCxZjDjc41xd3WwZDDh[4FqdnO2IHfsfYNw\2WwIIP5cpRp[XOnIHvpcoF{\S1\|IHnuJGhGUzJ7MzDj[YxteyxiRVO1NF0xNjMQvF2=	NVPCeHliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxOFk3QDRpPkG1NVQ6Pjh2PD;hQi=>
MIAPaCa2	NGWxPXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnXzO\|IhcHK\|	MYDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNTWFR[UOjMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwQVI2\|ryP	MlvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|M{izOVUoRjF7M{O4N\|U2RC:jPh?=
ST14A	MnjzSpVv[3Srb36gZZN{[Xl?		NFHVWWM3KGi{cx?=	NIrk[IZKdmirYnn0bY9vKG:oIFfTT{0{NWKndHGtcYVlcWG2ZXSgW451KHOrZ37hcIlv\yCrbjDoeY1idiCVVEG0RUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gc4Yh[mW2YT3jZZNmcW5iYYLveY5lKG63Y3zleZMh[W[2ZYKgOkBpenNiYomgcYlkem:\|Y3;wbYMh[W6jbInzbZM>	NX;MRmpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3NFg6OzdpPkKwO\|A5QTN5PD;hQi=>
neural precursor cells	MV;GeY5kfGmxbjDhd5NigQ>?			NG\3SIJKdmirYnn0bY9vKG:oIH7leZJwe3CqZYLlJJBzd2yrZnXyZZRqd25ib3[gcY92e2VibnX1doFtKHC{ZXP1dpNweiClZXzsd{BjgSCPVGSgZZN{[Xl?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzN{[zNUc,OTd2MUe2N\|E9N2F-
ReNcell VM	NGC2SmtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	MknwN{B2VQ>?	Mm\TO\|IhcHK\|	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKnTnPlcIwhXk1iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBifCB\|IIXNJIFnfGW{IEeyJIhzew>?	MojwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB5MEi5N\|coRjJyN{C4PVM4RC:jPh?=
HepG2	MULGeY5kfGmxbjDhd5NigQ>?	NFHTSY4{PCC3TR?=	NGizSosyOiCqcoO=	NVXMblN{UW6lcnXhd4UhcW5iZ3z1Z49{\SCrbnPvdpBwemG2aX;uJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG2IEO0JJVOKGGodHXyJFEzKGi{czDifUBodHWlb4PlJIF{e2G7	MmjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkexOVAoRjJ3NE[3NVUxRC:jPh?=
3T3L1	MWTGeY5kfGmxbjDhd5NigQ>?	NEHjNZY{PCC3TR?=	NVz0SY1POTJiaILz	M2XvT2lv[3KnYYPlJIlvKGeudXPvd4UhcW6lb4Lwc5JifGmxbjDpckBud3W\|ZTCzWFNNOSClZXzsd{BifCB\|NDD1UUBi\nSncjCxNkBpenNiYomg[4x2[2:\|ZTDhd5NigQ>?	NVz4e4N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlcyPTBpPkK1OFY4OTVyPD;hQi=>
HepG2	M1:4eGZ2dmO2aX;uJIF{e2G7	MXSzOEB2VQ>?	MXuxNkBpenN?	MU\Jcohq[mm2aX;uJI9nKEeVS{Pi[ZRiKGmwIHj1cYFvKEincFeyJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHKjdHnvJI9nKHCqb4PwbI9zgWyjdHXkJGdUN0eVIHH0JFM1KHWPIHHmeIVzKDF{IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	NETIeJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2O\|E2OCd-MkW0OlcyPTB:L3G+
Sf9	NIHLZ2NHfW6ldHnvckBie3OjeR?=		MlPCN\|AhdWmw	MXrJcohq[mm2aX;uJI9nKEeVS{Pi[ZRiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBk\WyuczD1d4lv\yCJU{GgZZMhe3Wkc4TyZZRmKGGwZDDb[4FudWF\|Mm3BWHAh[W[2ZYKgN\|AhdWmwIHL5JJNkcW6rdHzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC5yM{O4PO69VQ>?	NHzZUFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human HDLM-2 cell	NHHJXXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NUXTXXRDUW6qaXLpeIlwdiCxZjDoeY1idiCKRFzNMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyOUi0JO69VQ>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-H1770 cell	NUDHVYp5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NYDZcVB4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT6gTWM2OD1yLkK5N\|kzKM7:TR?=	NGTtfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human HOP-62 cell	NXvwdW1MT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MnnTTY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg2OjV4IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human JAR cell	NEO4cFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MXXJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMkGwOFQh\|ryP	NYPMZYN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human K5 cell	NIrNOGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NVjiSVlnUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6NCCLQ{WwQVEvPTN4OUig{txO	NV;XTINYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human MV-4-11 cell	NGi4ZZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M{npU2lvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjl4OEWg{txO	NXfGRZZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BT-549 cell	M{PrT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			Mm\hTY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6Ozd4IN88US=>	NEnIfIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human LB2241-RCC cell	NFzyW\|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MVPJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjJ2MT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR{OEe0JO69VQ>?	M{fSZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human GAMG cell	M{W4cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NEnVe5FKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PDB7IN88US=>	NGW0emc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human HMV-II cell	NV:yOllPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MnvCTY5pcWKrdHnvckBw\iCqdX3hckBJVVZvSVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlY4PjB5IN88US=>	NGmxe\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human RS4-11 cell	M4W2O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MoHUTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI1OTRzIN88US=>	MlPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-H1993 cell	M1Wz[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHTDS3lKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVk6OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRThwM{[1N\|Qh\|ryP	NWLZdZNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human IST-SL1 cell	M4XJSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWPJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlAzODRizszN	NH7PeIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human SK-OV-3 cell	Mo\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Mly3TY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4yODB{IN88US=>	M2PqNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human ESS-1 cell	M1fLT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MnTjTY5pcWKrdHnvckBw\iCqdX3hckBGW1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUmuOVk5PzJizszN	M3nwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human G-361 cell	M{LMbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWLJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUCuNVc6QCEQvF2=	M{ToflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human ALL-PO cell	MlfTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NHrRVoRKdmirYnn0bY9vKG:oIHj1cYFvKEGOTD3QU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjN2N{eg{txO	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NB5 cell	M1\VNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MVrJcohq[mm2aX;uJI9nKGi3bXHuJG5DPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFzLkKxOVch\|ryP	MnGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human DU-145 cell	NFnafGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NVvvfIxlUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS54NUO1JO69VQ>?	MnzjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NMC-G1 cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M2XOVGlvcGmkaYTpc44hd2ZiaIXtZY4hVk2FLVexJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvPzJ4NDFOwG0>	M1LqOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human RPMI-7951 cell	M{CyXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWnJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvN{m1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVEyNjd6NkSg{txO	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-H2009 cell	NFziVZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MUjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkCwPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{NjJ2Mkeg{txO	NW\KXGV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human LoVo cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NE\GR3ZKdmirYnn0bY9vKG:oIHj1cYFvKEyxVn:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{4{PzdzIN88US=>	NWfLVJpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human A2058 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXTJcohq[mm2aX;uJI9nKGi3bXHuJGEzODV6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUOuOFY6KM7:TR?=	NIPFeI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human D-566MG cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MnHSTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvQTR6MTFOwG0>	NGTMT2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human QIMR-WIL cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MUPJcohq[mm2aX;uJI9nKGi3bXHuJHFKVVJvV1nMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvPjN7NDFOwG0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human S-117 cell	Mle5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NUTzW2ZJUW6qaXLpeIlwdiCxZjDoeY1idiCVLUGxO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3NjRyMkKg{txO	M1XQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human YH-13 cell	NXy1WXJWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NVTGeoxsUW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3NjZ6NkWg{txO	M{nJVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human IGROV-1 cell	MnLUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MUHJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xO{4zODBzIN88US=>	NVXScmFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BHT-101 cell	NIPTfodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NFXXcXNKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPy54MEm5JO69VQ>?	NGC2PI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human MKN45 cell	NHXud5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NHzlTWZKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVgvPDF{ODFOwG0>	NF;rU2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human A498 cell	M17Semdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M3[5fmlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUG5MlQ2PDlizszN	Ml;DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human U-266 cell	M{DHWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkCuPFc6PyEQvF2=	NVTwO442RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BFTC-905 cell	M3npOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NYToTFB4UW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJzLkG4O\|kh\|ryP	NH\FZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human BxPC-3 cell	MmriS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MnvHTY5pcWKrdHnvckBw\iCqdX3hckBDgFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4{PTV2IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-SNU-1 cell	M{O0c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NIW0eFFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJzLkW1OVgh\|ryP	MlfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human SF539 cell	M4HKT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M4nzTGlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z3M{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNk4xOTl6IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human VA-ES-BJ cell	M1z5eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MkG2TY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIzNjV5NkOg{txO	NHfN[XE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human HuO-3N1 cell	NUfub4cyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NH7CRVhKdmirYnn0bY9vKG:oIHj1cYFvKEi3Tz2zUlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOi54MUWxJO69VQ>?	NHK3bJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human EM-2 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MmjBTY5pcWKrdHnvckBw\iCqdX3hckBGVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkKuOlY5QSEQvF2=	NFnwNnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human T98G cell	M2DCXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWjJcohq[mm2aX;uJI9nKGi3bXHuJHQ6QEdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Mz6zNFA6KM7:TR?=	NIDnbo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human SW1783 cell	NVO4WWlYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NH75VnhKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUe4N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{NjV{NEOg{txO	NFzCPJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human NKM-1 cell	M13iOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M3HneWlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yN{45PTF{IN88US=>	MoTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human KOSC-2 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NHzSXWJKdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1NjF{OUKg{txO	NVHyNHExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SW48 cell	M2P0dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NUDFUWgzUW6qaXLpeIlwdiCxZjDoeY1idiCVV{S4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPjB4NzFOwG0>	MoqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NCI-H28 cell	NWTjc4RKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MU\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOU4zOTB2IN88US=>	MlzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human 5637 cell	NFXMNZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MmXPTY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkWuPFEyOSEQvF2=	MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human NB69 cell	NY\4NplbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MXnJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nj6xO\|Y1KM7:TR?=	NWj0bmVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human HT-29 cell	NUDwPIVqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MYXJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkeuNVc2OiEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human PFSK-1 cell	NH3FeoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NXnsZXpWUW6qaXLpeIlwdiCxZjDoeY1idiCSRmPLMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPy53OUOg{txO	NIjOOGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human UACC-257 cell	M{nocWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NV;QSGc4UW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJ5Lke0N{DPxE1?	NXi0cYc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human D-423MG cell	Ml;nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NH7rbXBKdmirYnn0bY9vKG:oIHj1cYFvKERvNEKzUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPy57MUC2JO69VQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NH-12 cell	NELxR3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MlPyTY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUK4MlQxPTlizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human DEL cell	NWjmRlBsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NIXT[JdKdmirYnn0bY9vKG:oIHj1cYFvKESHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUK5MlA1PzRizszN	M2G2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human LS-513 cell	NXP2[4JMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NW\5V49SUW6qaXLpeIlwdiCxZjDoeY1idiCOUz21NVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{OC5zM{O0JO69VQ>?	NH3qcY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human NBsusSR cell	M{P0eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MnnITY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N\|AvPTZ5ODFOwG0>	MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human BV-173 cell	M{e0c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MnW1TY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNE44PjR7IN88US=>	NX\iNoF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human A101D cell	MorUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NYDGN29iUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMxNjl5OESg{txO	M1jkVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human LU-134-A cell	M2PuZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGxWNTF\|ND3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N\|EvODJ\|ODFOwG0>	MnXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human ES3 cell	M3LVOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NWfYcGhbUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{Ozd4IN88US=>	NXfvZZZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human NY cell	M4\zO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M{jOcWlvcGmkaYTpc44hd2ZiaIXtZY4hVlliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|Mj6yPVY2KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human NCI-H1975 cell	M33JfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MoHhTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG5O\|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Oi5\|NUiyJO69VQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human A704 cell	MmnaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NGfzSolKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE4zODV7IN88US=>	NWK1XW9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SK-MEL-24 cell	NFnkT5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1;QPGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwMkWyN{DPxE1?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human SW1088 cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NETNcppKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjN2NUKg{txO	NGi0ZnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODJ5MUSvK\|5USU6JRWK8M4E,
human SK-MEL-1 cell	Mn\RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NEDwUnlKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImsJGlEPTB;M{SuO\|E1KM7:TR?=	M3fjZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human MOLT-4 cell	M1PLZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MUXJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUO2MlE1PjdizszN	M{DndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human T47D cell	NXzFOYo5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M{X1NmlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUO3MlE3PDdizszN	NX\JfXpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human SW1710 cell	NXizOItYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NWWxe2FkUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Py5\|NkC4JO69VQ>?	MoLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human MKN7 cell	MmO3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NGXUZpFKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPE4xQTB7IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human CAL-72 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MkXETY5pcWKrdHnvckBw\iCqdX3hckBESUxvN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPE4yOTd6IN88US=>	M4izSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human AGS cell	M{HI[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHryRXhKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUO4MlIxOzlizszN	NUXxbGxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB{N{G0M{c,W0GQR1XSQE9iRg>?
human BE-13 cell	NEfOPFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NELLZplKdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N\|gvPzd6MzFOwG0>	Mnz5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVAzPzF2Lze+V2FPT0WUPD;hQi=>
human Calu-6 cell	M{PTXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYfJcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUO5MlY6PjRizszN	M2j4blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOjdzND:nQnNCVkeHUkyvZV4>
human CAL-27 cell	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MYLJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUS0MlAxPTRizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+
human BB49-HNC cell	MlG2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MYDJcohq[mm2aX;uJI9nKGi3bXHuJGJDPDlvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFQvODJ5ODFOwG0>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFI4OTRxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Myb; PubMed: 21795403 Mol Biol Cell Jurkat, K562, and RPMI 8226 cells were treated with or without 5 or 10 μM SB216763 for 8 h, and cell lysates were analyzed by immunoblotting. pGSK-3β / GSK-3β / E2F1 / β-catenin ; PubMed: 28042322 Theranostics Inhibition of GSK3β increased LSH expression. U251 (A) and HS683 (B) with treatment of SB216763 with different concentration as indicated were examined for the expression of LSH, p-GSK3β, GSK3β, E2F1, β-catenin and GAPDH by Western analysis. U251 (C) and HS683 (D) with treatment of 10μM SB216763 with time as indicated were examined for the expression of LSH, p-GSK3β, GSK3β, E2F1, β-catenin and GAPDH by Western analysis.	21795403 28042322
Growth inhibition assay	Cell viability; PubMed: 24779365 BMC Res Notes Cell viability of mouse embryonic stem cells after exposure to GSK3 inhibitors. (A) Cell viability of the mouse embryonic stem cell line ES-D3 after a three day treatment with different concentrations of BIO, SB-216763, CHIR-99021 and CHIR-98014. Cell viability was measured with the MTT assay. DMSO without inhibitors was used as vehicle control. Data are expressed as percentages normalized to the control condition without inhibitors. (B) Cell viability of the mouse embryonic stem cell line ES-CCE after a three day treatment with different concentrations of BIO, SB-216763, CHIR-99021 and CHIR-98014. Values are means ± SEM, n = 3-5. ANOVA plus Dunnett’s post hoc test. ** p ≤ 0.01, * p ≤ 0.05 compared to the control.	24779365

体内研究

SB 216763 按20 mg/kg 剂量处理患Bleomycin (BLM)诱导肺部炎症和纤维化的小鼠，通过显著抑制炎症细胞因子MCP-1和TNF-α的产量，显著抑制肺部炎症和纤维化，且显著提高BLM处理小鼠的寿命。SB 216763 处理，通过抑制肺泡上皮细胞损伤，而显著降低 BLM诱导的肺泡。^[4]

激酶实验：^[1]	- 合并 GSK-3 活性检测: 在不同浓度SB 216763存在时,在含1 nM 人GSK-3α, 50 mM MOPS pH 7.0,0.2 mM EDTA, 10 mM Mg(Ac)₂,7.5 mM β-巯基乙醇,5% (w/v)甘油,0.01% (w/v) Tween-20, 10% (v/v) DMSO, 及28 μM GS-2 肽底物的反应混合物中，测量GSK-3激酶活性。GS-2肽序列对应GSK-3使糖原合酶磷酸的地区。加入0.34 μCi [³³P]γ-ATP开始实验。全部ATP浓度为 10 μM。实验在室温下进行30分钟后，加入含21 mM ATP的1/3实验体积为2.5%(v/v) H₃PO₄，终止反应。样本在P30磷酸纤维垫上展开，然后在0.5% (v/v) H₃PO₄中冲洗6次。过滤垫密封到Wallac betaplate闪烁液的样品袋中。在 Wallac microbeta闪烁计数器中计算测定³³P 渗透到底物肽中的量。
细胞实验：^[3]	- 合并 Cell lines: BXPC-3, MIA-PaCa2, PANC1, ASPC1, 和CFPAC Concentrations: 溶于DMSO, 终浓度为~50 μM Incubation Time: 24, 48, 和72小时 Method: 使用不同浓度SB 216763处理细胞 24,48和 72小时。通过MTS检测测量相对细胞活力。使用 Hoechst染色而测定凋亡细胞。 (Only for Reference)
动物实验：^[4]	- 合并 Animal Models: 患Bleomycin (BLM)诱导的肺部炎症和纤维化的C57BL/6N小鼠 Dosages: 20 mg/kg Administration: 静脉注射 (Only for Reference)

参考文献

[4] Gurrieri C, et al. J Pharmacol Exp Ther, 2010, 332(3), 785-794.

- 合并

溶解度 (25°C)

体外	DMSO	23 mg/mL (61.95 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	4mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download SB216763 SDF

分子量	371.22
化学式	C₁₉H₁₂N₂O₂Cl₂
CAS号	280744-09-4
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

选择性强的GSK-3抑制剂

TWS119 : GSK-3β-selective, IC50 of 30 nM.
活性最高的GSK-3抑制剂

CHIR-98014 : GSK-3α, IC50=0.65 nM; GSK-3β, IC50=0.58 nM.
用于临床的GSK-3抑制剂

Tideglusib : Phase II for Alzheimer's disease.
最新的GSK-3抑制剂

AZD1080 : Orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with K_i of 6.9 nM and 31 nM, respectively.

研究领域

产品类型

定制您的化合物库

SB216763

客户使用Selleck生产的SB216763发表文献73篇：

产品安全说明书

GSK-3抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download SB216763 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

相关GSK-3产品